Correction: Efficacy and safety of BCMA-or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies - Scorecard - MDSpire

Correction: Efficacy and safety of BCMA-or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies

  • By

  • Jiashun Li

  • Ainikaer Abulaiti

  • Deyu Li

  • Yan Zhao

  • Paerhati Wahafu

  • Maerdan Maimaitiming

  • Shi Qiu

  • Yuxiang Zhang

  • Yaqin An

  • Wenxing Wang

  • Liangquan Shi

  • Maihemuti Yakufu

  • Li Shu

  • Guohua Li

  • Zhen Liu

  • June 22, 2026

  • 0 min

Share

Clinical Scorecard: Correction: Assessment of the Efficacy and Safety of CD3 Bispecific Antibodies Targeting BCMA or GPRC5D in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Evidence

At a Glance

CategoryDetail
ConditionRelapsed/Refractory Multiple Myeloma
Key MechanismsCD3 bispecific antibodies targeting BCMA or GPRC5D
Target PopulationPatients with relapsed/refractory multiple myeloma
Care SettingClinical trials and real-world studies

Key Highlights

  • Correction of funding statement in the published article
  • No change to scientific conclusions of the article
  • Focus on efficacy and safety of bispecific antibodies

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Patients with relapsed/refractory multiple myeloma

          Efficacy and safety of CD3 bispecific antibodies

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Correction: Efficacy and safety of BCMA-or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies

            • by Jiashun Li, Ainikaer Abulaiti, Deyu Li, Yan Zhao, Paerhati Wahafu, Maerdan Maimaitiming, Shi Qiu, Yuxiang Zhang, Yaqin An, Wenxing Wang, Liangquan Shi, Maihemuti Yakufu, Li Shu, Guohua Li, Zhen Liu

            • June 22, 2026

            Related Content

            Comparative efficacy and safety of etoposide plus PEG-rhG-CSF versus etoposide plus G-CSF for haematopoietic stem cell mobilisation in patients with multiple myeloma and lymphoma

            Exploring the Therapeutic Promise of γδ T Cells in Blood Disorders: Bridging Immunobiology and Clinical Innovation

            An ASCO preview: What to watch for at cancer research’s big meeting